SCHEMBL6569009

SCHEMBL6569009

O=C(NN=Cc1ccc(O)c(O)c1O)c1cccc(Cl)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.73
MAPT P10636 4/20 0.61
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
GAA P10253 1/20 0.60
HPGD P15428 1/20 0.60
MPI P34949 1/20 0.60
RECQL P46063 1/20 0.60
MCL1 Q07820 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
NTRK1 P04629 1/20 0.59
NPC1 O15118 4/20 0.58
RAB9A P51151 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6749843 1.00 KDM1A (0.73) KDM1AMAPTMEN1KMT2AKDM4E
SCHEMBL28433188 1.00 KDM1A (0.73) KDM1AMAPTMEN1KMT2AKDM4E
SCHEMBL6751416 0.87 KDM1A (0.81) KDM1AMAPTMEN1KMT2AKDM4E
SCHEMBL684219 0.87 KDM1A (0.81) KDM1AMAPTMEN1KMT2AKDM4E
SCHEMBL6751419 0.87 KDM1A (0.81) KDM1AMAPTMEN1KMT2AKDM4E
SCHEMBL684639 0.87 KDM1A (0.81) KDM1AMAPTMEN1KMT2AKDM4E
SCHEMBL685010 0.86 KDM1A (0.67) KDM1AMAPTMEN1KMT2AKDM4E
SCHEMBL684660 0.86 KDM1A (0.74) KDM1AMAPTMEN1KMT2AKDM4E
SCHEMBL6569227 0.85 KDM1A (0.77) KDM1AMAPTMEN1KMT2AKDM4E
SCHEMBL6569224 0.85 KDM1A (0.77) KDM1AMAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO KDM1A 2684/4885MAPT 3140/4885MEN1 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.